Gland Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	-	33,591	25,562	3,571	19,089	3,188
Short-Term Investments	-	-	3,960	15,817	18,539	27,720
Trading Asset Securities	-	-	-	-	-	1,549
Cash & Short-Term Investments	33,591	33,591	29,522	19,388	37,628	32,457
Cash Growth	13.78%	13.78%	52.27%	-48.48%	15.93%	8.08%
Accounts Receivable	-	20,368	16,507	16,482	9,587	12,097
Other Receivables	-	874.59	1,106	641.42	771.8	825.85
Receivables	-	21,243	17,613	17,123	10,360	12,928
Inventory	-	17,854	17,333	16,763	19,782	12,292
Prepaid Expenses	-	409.48	392.4	384.65	138.22	141.61
Other Current Assets	-	2,171	2,969	2,793	1,100	702.63
Total Current Assets	-	75,268	67,829	56,452	69,008	58,521
Property, Plant & Equipment	-	44,320	39,439	38,302	17,361	16,804
Long-Term Investments	-	-	-	6,545	-	2,000
Goodwill	-	2,939	2,482	2,423	-	-
Other Intangible Assets	-	1,086	1,057	1,122	116.61	125.35
Long-Term Deferred Tax Assets	-	623.25	520.68	504.37	-	-
Other Long-Term Assets	-	872.31	921.19	1,265	1,290	886.04
Total Assets	-	125,108	112,249	106,612	87,775	78,336

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Accounts Payable	-	8,339	8,204	7,677	5,874	4,629
Accrued Expenses	-	2,941	2,572	2,334	477.42	461.14
Short-Term Debt	-	1,298	1,561	1,671	-	-
Current Portion of Long-Term Debt	-	436.26	354.76	461.21	5.6	1.12
Current Portion of Leases	-	169.28	150.32	177.05	1.49	1.49
Current Income Taxes Payable	-	628.6	736.88	516.37	9.85	179.79
Current Unearned Revenue	-	411.87	417.76	337.42	8.12	8.87
Other Current Liabilities	-	1,860	1,652	808.48	915.35	539.34
Total Current Liabilities	-	16,084	15,648	13,984	7,291	5,820
Long-Term Debt	-	699.25	776.64	1,065	32.61	38.21
Long-Term Leases	-	233.02	294.87	346.79	4.83	6.61
Long-Term Unearned Revenue	-	412.46	413.85	404.86	-	-
Long-Term Deferred Tax Liabilities	-	2,144	2,148	2,201	842.03	877.6
Other Long-Term Liabilities	-	1,956	1,460	1,372	17.33	17.33
Total Liabilities	-	21,529	20,742	19,374	8,188	6,760

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Common Stock	-	164.76	164.76	164.71	164.7	164.3
Additional Paid-In Capital	-	19,330	19,330	19,292	19,284	18,954
Retained Earnings	-	78,907	71,600	67,910	60,185	52,375
Comprehensive Income & Other	-	5,177	412.28	-128.27	-46.81	83.32
Shareholders' Equity	103,580	103,580	91,507	87,238	79,587	71,576
Total Liabilities & Equity	-	125,108	112,249	106,612	87,775	78,336

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Total Debt	2,836	2,836	3,137	3,722	44.53	47.43
Net Cash (Debt)	30,755	30,755	26,385	15,666	37,584	32,410
Net Cash Growth	16.56%	16.56%	68.42%	-58.32%	15.96%	8.10%
Net Cash Per Share	186.40	186.45	160.15	95.10	228.22	196.97
Filing Date Shares Outstanding	164.83	164.76	164.76	164.71	164.7	164.3
Total Common Shares Outstanding	164.83	164.76	164.76	164.71	164.7	164.3
Working Capital	-	59,184	52,181	42,468	61,717	52,701
Book Value Per Share	628.68	628.68	555.41	529.65	483.22	435.64
Tangible Book Value	99,555	99,555	87,968	83,694	79,471	71,451
Tangible Book Value Per Share	604.25	604.25	533.93	508.13	482.51	434.87
Land	-	11,152	9,518	9,305	634.58	627.07
Buildings	-	8,179	6,391	5,934	3,328	3,203
Machinery	-	42,812	35,592	30,449	18,844	16,940
Construction In Progress	-	3,422	1,506	2,379	1,772	1,807